Long-term survival outcomes of duodenal adenocarcinoma: A cohort study with 15-year single-center experience

Table 1 Characteristics of the patients with duodenal adenocarcinoma

Variable	n (%)
Age, mean (SD)	60.7 (12.5)
Female gender, n (%)	85 (40.9)
BMI (kg/m2), mean (SD)	22.9 (3.8)
Preoperative lab, n (%)
CA199 (U/mL) > 37	50 (24.0)
CEA (ug/L) > 5	64 (30.8)
Operational types, n (%)
Pancreatoduodenectomy	123 (71.5)
Local resection	19 (11.1)
Palliative operation	30 (17.4)
Radical operation, n (%)	142 (82.6)
Total number of harvested lymph nodes, median (IQR)	12 (8-16)
Positive lymph nodes, n (%)	51 (35.9)
Tumor stage, n (%)
Stage I	54 (26.0)
Stage II	43 (20.7)
Stage III	57 (27.4)
Stage IV	54 (26.0)
Tumor location, n (%)
1st portion	99 (47.6)
1st-2nd portion	64 (30.8)
2nd portion	13 (6.3)
3rd portion	5 (2.4)
4th portion	27(13.0)
Postoperative complications, n (%)	46 (32.2)
Hospital stays (days), mean (SD)	22.5 (5.1)
Pathological type1, n (%)
Adenocarcinoma	147 (85.5)
Non-adenocarcinoma	25 (14.5)
Pathological differentiation2, n (%)
Poorly differentiation	41 (28.9)
Medium-high differentiation	101 (71.1)
Pancreatic invasion, n (%)	68 (47.7)
Vascular invasion, n (%)	50 (35.5)
Nerve invasion, n (%)	69 (48.3)
Lymphatic vessel invasion3, n (%)	51(35.9)
KRAS mutation, n (%)	6 (15.38)
DMMR/MSI-H, n (%)	7 (7.22)
Her-2 positive, n (%)	56 (49.12)
Ki-67 mutation, n (%)	7 (20.59)
Adjuvant therapy, n (%)	26 (18.3)

¹Missing value in overall cohort: 3.

²Missing value in overall cohort: 5.

³Missing value in overall cohort: 10.

Table 2 Uni- and multivariate analysis for overall survival

Characteristics	Univariate analysis		Multivariate analysis
	Hazard ratio	P value	Hazard ratio	P value
Age (years; ≥ 65 vs < 65 = 1.00)	1.01 (0.99-1.02)	0.24
Gender, female (vs male = 1.00)	0.80 (0.54-1.21)	0.30
CA199 (U/mL; ≥ 37 vs < 37 = 1.00)	2.92 (1.96-4.33)	< 0.001	1.10 (0.60-2.01)	0.76
Radical operation (vs without radical operation = 1.00)	4.912 (2.98-8.11)	< 0.001
AJCC stage IV (vs AJCC stage I-III = 1.00)	3.04 (2.40-3.86)	< 0.001	4.75 (2.70-8.47)	< 0.001
Postoperative complications (vs without postoperative complications = 1.00)	1.22 (0.77-1.95)	0.40
Pancreatic invasion (vs without Pancreatic invasion = 1.00)	5.07 (2.91-8.85)	< 0.001	2.68 (1.41-5.11)	0.003
Poorly differentiation (vs medium-high differentiation = 1.00)	1.88 (1.17-3.00)	0.009
KRAS mutation (vs KRAS wild type = 1.00)	1.24 (0.35-4.29)	0.73
dMMR/MSI-H (vs PMMR/MSS = 1.00)	0.51 (0.12-2.11)	0.35
Her-2 positive (vs Her-2 negative = 1.00)	1.87 (0.68-5.13)	0.23
Adjuvant therapy (vs without adjuvant therapy = 1.00)	2.52 (1.23-5.15)	0.01	2.71 (1.30-5.62)	0.008

AJCC: American Joint Committee on Cancer.